Physician profile
Jacque Angerstein
NPI 1750367629
$4,366.01
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,643 · 2020: $1,658 · 2021: $937 · 2023: $56.81 · 2024: $72.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $129.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $603.44 | 2019-2021 | |
| Allergan, INC. | $590.72 | 2019-2020 | |
| Pfizer INC. | $334.30 | 2019-2021 | |
| Abbvie INC. | $320.06 | 2019-2023 | Vraylar |
| Gilead Sciences, INC. | $263.23 | 2019-2021 | |
| Lilly USA, LLC | $235.95 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.46 | 2019-2021 | |
| Amgen INC. | $233.80 | 2019-2021 | |
| Glaxosmithkline, LLC. | $147.54 | 2019-2023 | Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $118.58 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.90 | 2019-2021 | |
| Adlon Therapeutics L.P. | $104.80 | 2020-2021 | |
| Eisai INC. | $99.26 | 2020 | |
| Novo Nordisk INC | $97.13 | 2019-2021 | |
| Neos Therapeutics, Lp | $93.96 | 2020-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacque Angerstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.